Emerging Policy Response Center

AdvaMed’s Q1 2025 report focuses on tariffs, policy action, and how we’re protecting Medtech innovation.

WASHINGTON – Today AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker:

Details a sweeping tariff hike to 84% on Chinese imports and de minimis increases, aiming to protect U.S. economic and national security.

Washington, D.C.– AdvaMed, the Medtech Association, released the following statement from President and CEO Scott Whitaker:

“Our country is the birthplace of the medical device and technology industry and leads the world in innovation and production because U.S. policies promote innovation. We support any and every policy that allows us to maintain our position of global primacy in every aspect of medical innovation imaginable. We also fully support the President’s goal of moving as much manufacturing into the United States as possible.

Exclusive member webinar on tariffs, customs, USMCA rules of origin, and compliance strategies with expert Larry Friedman. Air Date April 4, 2025. Now On Demand!

Tariffs on medical goods threaten healthcare costs, access, and supply chains. Leading health groups urge exemptions to safeguard patient care.

Tariffs on medtech could disrupt supply chains, increase costs, and delay care. Exemptions are needed to protect hospitals, patients, and innovation.

An overview of the Make America Healthy Again Commission, its mission to address chronic disease in the U.S., and policy initiatives aimed at improving public health.